Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 1
2017 1
2019 1
2020 1
2021 1
2022 7
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Recent advances in the diagnosis and management of cluster headache.
Schindler EAD, Burish MJ. Schindler EAD, et al. BMJ. 2022 Mar 16;376:e059577. doi: 10.1136/bmj-2020-059577. BMJ. 2022. PMID: 35296510 Review.
Cluster headache, a primary headache disorder, consists of short (15-180 minutes), frequent (up to eight a day), unilateral attacks of facial pain with associated ipsilateral autonomic features and restlessness. ...This review covers the clinical, pathophysio …
Cluster headache, a primary headache disorder, consists of short (15-180 minutes), frequent (up to eight a day), unilateral at …
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.
Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M. Perez N, et al. Eur Neuropsychopharmacol. 2023 Nov;76:61-76. doi: 10.1016/j.euroneuro.2023.07.011. Epub 2023 Aug 7. Eur Neuropsychopharmacol. 2023. PMID: 37557019 Free article. Review.
Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. . …
Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted …
[The use of psilocybin for treatment-resistant depression].
Johannesdottir A, Sigurdsson E. Johannesdottir A, et al. Laeknabladid. 2022 Sep;108(9):403-410. doi: 10.17992/lbl.2022.09.706. Laeknabladid. 2022. PMID: 36040772 Free article. Icelandic.
Our goal is to review current knowledge on psilocybin and its efficacy in TRD. Literature searches were done on PubMed, Web of Science and Google Scholar, references reviewed in identified articles and other articles found on the website of COMPASS Pathways. ...Comm …
Our goal is to review current knowledge on psilocybin and its efficacy in TRD. Literature searches were done on PubMed, Web of …
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. Rosenblat JD, et al. Can J Psychiatry. 2023 Jan;68(1):5-21. doi: 10.1177/07067437221111371. Epub 2022 Aug 17. Can J Psychiatry. 2023. PMID: 35975555 Free PMC article. Review.
RESULTS: Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. ...There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). ...
RESULTS: Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. ...There was only one ope …
Use of Psychedelics for Pain: A Scoping Review.
Goel A, Rai Y, Sivadas S, Diep C, Clarke H, Shanthanna H, Ladha KS. Goel A, et al. Anesthesiology. 2023 Oct 1;139(4):523-536. doi: 10.1097/ALN.0000000000004673. Anesthesiology. 2023. PMID: 37698433 Free article. Review.
This scoping review was conducted to identify human studies in which psychedelic agents were used for the treatment of pain. ...Overall, psychedelics appear to show promise for analgesia in patients with certain headache disorders and cancer pain diagnoses. Future s …
This scoping review was conducted to identify human studies in which psychedelic agents were used for the treatment of pain. ...Overa …
Are psychedelics the answer to chronic pain: A review of current literature.
Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, Vissers KCP, van der Wal SEI. Kooijman NI, et al. Pain Pract. 2023 Apr;23(4):447-458. doi: 10.1111/papr.13203. Epub 2023 Jan 11. Pain Pract. 2023. PMID: 36597700 Review.
AIMS: We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. CONTENT: Chronic pain is a common and complex problem, with an unknown etiology. ...In cancer and palliative related pain, the analgesic potentia …
AIMS: We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. CONTE …
The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.
Kaminski D, Reinert JP. Kaminski D, et al. Ann Pharmacother. 2023 Oct 30:10600280231205645. doi: 10.1177/10600280231205645. Online ahead of print. Ann Pharmacother. 2023. PMID: 37902038 Review.
OBJECTIVE: The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions. ...Following the application of inclusion and exclusion criteria, 16 studies were ultimately …
OBJECTIVE: The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of p …
Classical psychedelics for the treatment of depression and anxiety: A systematic review.
Muttoni S, Ardissino M, John C. Muttoni S, et al. J Affect Disord. 2019 Nov 1;258:11-24. doi: 10.1016/j.jad.2019.07.076. Epub 2019 Jul 30. J Affect Disord. 2019. PMID: 31382100
This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression. ...The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure. ...
This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression. ...The most co …
The Potential of Psychedelics for the Treatment of Episodic Migraine.
Schindler EAD. Schindler EAD. Curr Pain Headache Rep. 2023 Sep;27(9):489-495. doi: 10.1007/s11916-023-01145-y. Epub 2023 Aug 4. Curr Pain Headache Rep. 2023. PMID: 37540398 Review.
PURPOSE OF REVIEW: This review presents the existing literature of and a framework for how psychedelic drugs might be applied as therapeutic agents in episodic migraine. ...The existing evidence supports the continued investigation of psilocybin and other psy …
PURPOSE OF REVIEW: This review presents the existing literature of and a framework for how psychedelic drugs might be applied …
Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies.
Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M. Rusanen SS, et al. Curr Pain Headache Rep. 2022 Aug;26(8):623-637. doi: 10.1007/s11916-022-01063-5. Epub 2022 Jun 27. Curr Pain Headache Rep. 2022. PMID: 35759175 Free PMC article. Review.
PURPOSE OF REVIEW: The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surveys. ...RECENT FINDINGS: No systematic review have been conducted of these studies previously. A systematic literature search with a s …
PURPOSE OF REVIEW: The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surve …
27 results